Synthetic Biologics Reports First Quarter 2012 Financial ResultsSynthetic Biologics Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, today reported financial results for the three months ended March 31, and summarized operational highlights.
Synthetic Biologics Announces Completion Of Enrollment In Trial Of MS DrugSynthetic Biologics Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and medicines for serious illnesses, announced that patient enrollment has been completed in a Phase II clinical trial evaluating the efficacy and safety of Synthetic Biologics' proprietary oral formulation of estriol (Trimesta) for the treatment of relapsing-remitting multiple sclerosis.
HR Notices From February 7The latest staffing, boardroom and leadership changes at Michigan's technology-focused companies and institutions

More From CBS Detroit

Best Christmas Light Displays
Best Holiday Drink Ideas
Top Hidden Destinations

Watch & Listen